Regarding: Alpha‐1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study

Journal of Internal Medicine, vol. 297, pp. 234–235

Abstract

M.F. received consulting fees from Takeda Pharmaceuticals and honoraria from CSL Behring, Grifols Inc and Takeda Pharmaceuticals. P.S. reports receiving grants and honoraria from Arrowhead Pharmaceuticals, CSL Behring, Grifols Inc, consulting fees or honoraria from Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, Dicerna Pharmaceuticals, GSK, Intellia Pharmaceuticals, Takeda Pharmaceuticals, Novo Nordisk and Ono Pharmaceuticals, participating in leadership or fiduciary roles in Alpha-1-Deutschland, Alpha-1 Global, and material transfer support for Vertex Pharmaceuticals and Dicerna Pharmaceuticals. All other authors have no conflicts of interest to disclose. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Authors 4

1. Malin Fromme Aachen Medical Clinic III Gastroenterology Medical Clinic III

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Medical Clinic III Gastroenterology, Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER) Aachen Germany

   Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany

2. Katharina Remih Aachen Medical Clinic III Gastroenterology Medical Clinic III

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Medical Clinic III Gastroenterology, Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER) Aachen Germany

   Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany

3. Carolin Victoria Schneider Aachen Medical Clinic III Gastroenterology Medical Clinic III

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Medical Clinic III Gastroenterology, Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER) Aachen Germany

   Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany

4. Pavel Strnad corresponding Aachen Medical Clinic III Gastroenterology Medical Clinic III

   RWTH Aachen University · Universitätsklinikum Aachen

   Affiliation as printed

   Medical Clinic III Gastroenterology, Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER) Aachen Germany

   Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany